NASDAQ:VERUVeru Stock Price, Forecast & News

Veru's stock was trading at $3.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VERU stock has increased by 13.8% and is now trading at $3.64. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veru.

Veru is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Veru.

Veru Inc (NASDAQ:VERU) released its earnings results on Wednesday, May, 13th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.03. The firm earned $9.94 million during the quarter, compared to analyst estimates of $11.06 million. Veru had a negative return on equity of 31.14% and a negative net margin of 25.53%. View Veru's earnings history.

4 equities research analysts have issued 12 month price targets for Veru's stock. Their forecasts range from $6.00 to $12.00. On average, they anticipate Veru's stock price to reach $8.25 in the next year. This suggests a possible upside of 126.6% from the stock's current price. View analysts' price targets for Veru.

News coverage about VERU stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Veru earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutVeru.

Veru saw a decrease in short interest in May. As of May 15th, there was short interest totaling 177,000 shares, a decrease of 48.7% from the April 30th total of 344,900 shares. Based on an average daily trading volume, of 309,200 shares, the short-interest ratio is currently 0.6 days. Approximately 0.4% of the shares of the company are short sold. View Veru's Current Options Chain.

Some companies that are related to Veru include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Prestige Consumer Healthcare (PBH), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Inter Parfums (IPAR), Medifast (MED), Revlon (REV) and Nature's Sunshine Products (NATR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Corbus Pharmaceuticals (CRBP), Opko Health (OPK), Sorrento Therapeutics (SRNE), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Viking Therapeutics (VKTX), Alibaba Group (BABA), Genocea Biosciences (GNCA), Novavax (NVAX) and Zynerba Pharmaceuticals (ZYNE).

Veru trades on the NASDAQ under the ticker symbol "VERU."

Veru's stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.59%), Wedge Capital Management L L P NC (0.51%), Morgan Stanley (0.50%), EAM Investors LLC (0.48%), BlackRock Inc. (0.35%) and Wells Fargo & Company MN (0.20%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View institutional ownership trends for Veru.

VERU stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., and State Street Corp. View insider buying and selling activity for Veru.

VERU stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Caxton Associates LP, Acadian Asset Management LLC, Two Sigma Advisers LP, Citigroup Inc., UBS Group AG, and Engineers Gate Manager LP. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, K Gary Barnette, and Michele Greco. View insider buying and selling activity for Veru.

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VERU stock can currently be purchased for approximately $3.64.

Veru has a market capitalization of $240.60 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe.

The official website for Veru is www.veruhealthcare.com.

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected]